141 results about "Notoginsenoside R1" patented technology

The invention provides a radix notoginseng extract which contains 5-10% of notoginsenoside R1, 25-36% of ginsenoside Rg1, 2.5-5% of ginsenoside Re, 30-39% of ginsenoside Rb1, 5-10% of ginsenoside Rd and at least 2% of ginsenoside Rf, ginsenoside Rh1, ginsenoside Rc, ginsenoside Rb2 and ginsenoside Rg3, wherein the ginsenoside R1, the ginsenoside Rg1, the ginsenoside Re, the ginsenoside Rb1 and the ginsenoside Rd account for 75-95% of the total weight. The invention also provides a preparation method of the radix notoginseng extract. The radix notoginseng extract prepared by the method has little impurities, the purity of the component of total saponin is higher, and especially, the components of the ginsenoside Rf, the ginsenoside Rh1, the ginsenoside Rc, the ginsenoside Rb2, the ginsenoside Rg3 and the like with very low content are purified. The medicinal preparation prepared by the radix notoginseng extract has better curative effect and higher safety.

The invention discloses a method for increasing the content of notoginsenoside R1 in panax notoginseng. Before the panax notoginseng is harvested, a salicylic acid solution is sprayed to panax notoginseng plants. According to the method, due to the fact that the salicylic acid solution is used for processing the panax notoginseng plants before the panax notoginseng is harvested, the content of the notoginsenoside R1 in the panax notoginseng is increased, the method can be used on a large scale in a conventional panax notoginseng cultivating method so that the notoginsenoside R1 can be industrially produced on a large scale, and the requirement of the market for the notoginsenoside R1 is met.

The invention discloses a new use of notoginsenoside R1 in the preparation of medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods as an active component. Experiment results show that the notoginsenoside R1 has an inhibition effect on the NF-kappa B signal pathway, and has substantial prevention and treatment effects on the NF-kappa B signal pathway mediated ulcerative colonitis, so the notoginsenoside R1 can be developed to medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods. The new use urges the notoginsenoside R1 to fully perform its medicinal values, and is very important for researching and applying Panax Notoginseng.

The invention discloses a method for preparing astragalus Sanxian soup flexible nano-liposome. The preparation method comprises the following steps: (1) weighing lecithin, cholesterol, astragaloside, icariin and notoginsenoside R1 according to a ratio, adding the raw materials into a container, and adding a methanol-chloroform mixed solvent, so that the raw materials are fully dissolved; (2) arranging the dissolved raw materials on a rotary evaporator, performing reduced pressure spin evaporation to remove an organic solvent in a constant temperature water bath, and performing vacuum drying overnight; (3) preparing a sodium cholate PBS solution, adding ethylene diamine tetramethylidene phosphoric acid into the sodium cholate PBS solution, adding the mixed solution into the dried raw materials, and performing normal pressure spin evaporation in the constant temperature water bath, thereby preparing primary suspension of the liposome; and (4) ultrasonically oscillating the primary suspension of the liposome, and finally sequentially squeezing the primary suspension to pass through microfiltration membranes with the pore diameters of 0.80mu m, 0.45mu m and 0.22mu m to obtain the flexible nano-liposome. The liposome disclosed by the invention has the advantages of uniform particle size, high encapsulation efficiency and high targeting property.

The invention is suitable for the field of medicines and provides a drug composition for preventing and treating related diseases of ischemic stroke. The drug composition comprises the following components in parts: 1.0-3.5 parts of notoginsenoside R1, 4.0-7.5 parts of ginsenoside Rg1, 3.5-7.5 parts of ginsenoside Rb1, 1.0-3.0 parts of ginsenoside Re, 0.03-0.15 part of astragaloside, 0.02-0.010 part of calycosin-7-O-beta-D-glucopyranoside, 0.01-0.10 part of harpagoside, 0.002-0.010 part of cinnamic acid, 0.45-1.5 parts of salvianolic acid B, 0.02-0.10 part of cryptotanshinone and 0.02-0.10 part of tanshinone IIA. The drug composition provided by the invention has the functions of promoting blood circulation and removing blood stasis, supplementing qi and nourishing yin, can be used for preventing and treating the related diseases of the ischemic stroke and is capable of overcoming the shortcomings of component complexity and the like of traditional compound traditional Chinese medicine preparations.

The invention relates to a set of UDP-glycosyl transferases capable of catalyzing carbohydrate chain extension, and applications thereof, and more specifically provides a catalytic reaction used for obtaining ginsenoside products including ginsenoside Rb1, ginsenoside Rb3, gypenoside LXXV, gypenoside XVII, notoginsenoside U and, notoginsenoside R1, and notoginsenoside R2 through catalyzing of C-20site 1th glycosyl and C-6 site 1th glycosyl of tetracyclic triterpene substances with glycosyl transferases GT29-32, GT29-33, GT29-34, GT29-4, GT29-5, GT29-7, GT29-9, GT29-11, GT29-13, GT29-17, GT29-18, GT29-24, and GT29-25, and derived peptides thereof through carbohydrate chain extension. The glycosyl transferases can be used for construction of artificially synthesized ginsenosides and a plurality of novel ginsenosides and derivatives of ginsenosides.

The invention relates to a detection method of a traditional Chinese preparation for treating a stomach illness. The detection method of the traditional Chinese preparation comprises qualitative identification and content determination conducted on a monarch drug pseudo-ginseng, namely,pseudo-ginseng identification by adopting a thin-layer chromatography and content determination of notoginsenoside R1, ginsenoside Rg1 and ginsenoside Rb1 in the pseudo-ginseng by adopting high efficiency liquid chromatography. Compared with an existing quality control method, the quality control method has the advantages of being accurate and good in reproducibility. By adopting the method, the related medicine quality can be accurately controlled, the medicine usage risk can be reduced, and the product quality can be improved.

The invention belongs to the field of traditional Chinese medicine and particularly relates to a method for measuring the content of main active ingredients in xiaoshuan tongluo tablets. According to the measurement method, the content of ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1 in the xiaoshuan tongluo tablets can be measured simultaneously with an HPLC (high performance liquid chromatography) method, a reference substance mixed solution I and a test solution I are injected into a liquid chromatograph respectively according to chromatographic conditions, the injection volume of the reference substance mixed solution I is 10 mu L, the injection volume of the test solution I is 5 mu L, the chromatographic peak area is recorded, and the content is calculated with an external standard method. Meanwhile, according to the measurement method, the content of astragaloside is measured with an ELSD (evaporative light-scattering detector) method, a reference substance mixed solution II and a test solution II are injected into the liquid chromatograph respectively according to chromatographic conditions, the injection volumes of the reference substance mixed solution II are 5 mu L and 10 mu L respectively, the injection volume of the test solution II is 10-20 mu L, the chromatographic peak area is recorded, and the content is calculated according to a two-point external standard method logarithmic equation.